Form 4: Revolution Medicines CFO Sells Shares for Tax Obligations
Insider Transaction Report
Revolution Medicines' CFO, Jack Anders, sold 2,320 shares of common stock on September 16, 2025, at $45.8249 per share to cover tax withholding from RSU vesting.
Summary
- Jack Anders, Chief Financial Officer of Revolution Medicines, Inc. (RVMD), disposed of 2,320 shares of common stock.
- The transaction occurred on September 16, 2025, at a price of $45.8249 per share.
- The sale was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023.
- The purpose of the sale was to satisfy the reporting person's tax withholding obligation upon the vesting of restricted stock units (RSUs) after July 15, 2023.
- Following this transaction, Jack Anders beneficially owns 110,994 shares of common stock, which includes 48,275 restricted stock units.
Sentiment
Score: 5
Explanation: The transaction is a pre-planned, non-discretionary sale for tax withholding purposes upon RSU vesting, which is a routine event for executives and does not reflect a change in the company's operational outlook or the insider's confidence.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
No specific forward-looking statements or guidance regarding company performance or strategy are provided in this Form 4 filing.
Management Comments
- The transaction was executed to satisfy the reporting person's tax withholding obligation upon the vesting of restricted stock units, as per a Rule 10b5-1 plan adopted on May 31, 2023.
Industry Context
This Form 4 filing details an insider transaction and does not provide broader industry context or trends.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Minimal impact on shareholders, employees, customers, suppliers, and creditors as this is a routine, pre-planned transaction for tax purposes and does not signal a change in company strategy or performance.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 05/31/2023 | Rule 10b5-1 instruction letter adopted by Jack Anders. |
| 07/15/2023 | Date after which restricted stock units (RSUs) vested, triggering tax withholding obligations. |
| 09/16/2025 | Date of common stock transaction (sale). |
| 09/18/2025 | Date the Form 4 was signed by Jack Anders. |
Recommendation
holdThis Form 4 reports a routine, pre-planned sale of shares by an executive to cover tax obligations upon RSU vesting. Such a transaction, executed under a Rule 10b5-1 plan, is non-discretionary and does not typically indicate a change in the executive's outlook on the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Revolution Medicines, RVMD, Jack Anders, CFO, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.